Efectos secundarios del tratamiento para la leucemia linfoblástica aguda .. ( PEG-L asparaginasa; Oncaspar®) administrada por inyección. O Vincristina. L-asparaginase, definition: alkylating anticancer drug used in the treatment of L -asparaginasa, definition: fármaco alquilante antineoplásico, utilizado para el Los efectos secundarios más comunes son nauseas, vómitos. y otros efectos adversos de este grupo de fármacos, ya que estos pacientes los efectos citotóxicos de la quimioterapia son mediados por diversos . Actinomicina D, metotrexato, andrógenos, L-asparaginasa, procarbazina, vincristina.

Author: Zura Akikus
Country: Guadeloupe
Language: English (Spanish)
Genre: History
Published (Last): 7 May 2005
Pages: 161
PDF File Size: 18.7 Mb
ePub File Size: 14.79 Mb
ISBN: 359-1-98616-755-3
Downloads: 92377
Price: Free* [*Free Regsitration Required]
Uploader: Douzahn

How to search [pdf]. The duration of this interval must be approved by the Onyx study medical monitor.

l-asparaginasa efectos adversos pdf – PDF Files

Review by the L-asparagniasa Authority or Ethics Committee in the country concerned. Combination product that efecos a device, but does not involve an Advanced Therapy. Restricciones de tratamientos previos: Pneumonia AND sponsor name. Title of the trial for lay people, in easily understood, i.

Committee on Advanced therapies CAT has issued a classification for this product. Age 18 years or younger at the time of study treatment initiation. Cancer AND drug name. Date on which this record was first entered in the EudraCT database:.

Clinical trials

Subjects must have fully recovered from the acute toxic effects of all previous chemotherapy, immunotherapy, or radiotherapy treatment before enrollment. Definition of the end of efectis trial and justification where it is not the last visit of the last subject undergoing the trial. Active treatment for graft-versus-host disease 6.


Positive culture for bacteria or fungus within 14 days of the initiation of therapy 7. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur.

Adveros 1b – To assess the safety and tolerability of carfilzomib, alone and in combination with induction chemotherapy, for the treatment of children with adveersos or refractory acute lymphoblastic leukemia ALL -To determine the maximum tolerated dose MTD of carfilzomib in combination with induction chemotherapy.

The IMP has been designated in this indication as an orphan drug in the Community. The trial involves single site in the Member State concerned.

Karnofsky or Lansky scores? IMP with orphan designation in the indication. Both Female Only Male Only.

Son aptos los sujetos que hayan sufrido una alergia previa a la asparaginasa PEG pero que puedan recibir Erwinia. Known allergy to Captisol a cyclodextrin derivative used to solubilize carfilzomib; for a complete listing of Captisol-enabled drugs, see the Ligand Pharmaceuticals, Inc.

Plans for treatment or care after the subject has ended the participation in the trial if it is different from the expected normal treatment l-aspaaraginasa that condition. Trials with results Trials without results Clear advanced search filters. For these items you should use the filters and not add them to your search terms in the text field. Trials with results Trials without results. Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results information on: EU Clinical Trials Register.


Subjects must have a serum creatinine level that is? Subjects are under 18 years old. A group of cancers that usually begins in the bone marrow and results in high numbers of abnormal white blood cells.

Relapsed or Refractory Acute Lymphoblastic Leukemia. Time to toxicity will be evaluated to differentiate single-agent carfilzomib from carfilzomib in combination with induction chemotherapy? Adequate liver function, defined as both of l-azparaginasa following: Los sujetos deben haber finalizado todo tipo de inmunoterapia activa p. Adverrsos advanced search filters. Known allergy to any of the drugs used in the study. Subjects who have had a previous allergy to PEG-asparaginase but can receive Erwinia are eligible.